List of Bethkis drug patents

Bethkis is owned by Chiesi.

Bethkis contains Tobramycin.

Bethkis has a total of 3 drug patents out of which 3 drug patents have expired.

Expired drug patents of Bethkis are:

  • US7939502
  • US6987094
  • US7696178

Bethkis was authorised for market use on 12 October, 2012.

Bethkis is available in solution;inhalation dosage forms.

Bethkis can be used as management of cystic fibrosis patients.

The generics of Bethkis are possible to be released after 22 September, 2022.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7939502 CHIESI Optimised formulation of tobramycin for aerosolization
Jun, 2022

(7 months ago)

US6987094 CHIESI Optimized formulation of tobramycin for aerosolization
Sep, 2022

(4 months ago)

US7696178 CHIESI Optimised formulation of tobramycin for aerosolization
Sep, 2022

(4 months ago)

Drugs and Companies using TOBRAMYCIN ingredient

Market Authorisation Date: 12 October, 2012

Treatment: Management of cystic fibrosis patients

Dosage: SOLUTION;INHALATION

How can I launch a generic of BETHKIS before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic